Dicyclomine

Identification

Summary

Dicyclomine is an antimuscarinic agent used to treat IBS.

Brand Names

Bentyl

Generic Name

Dicyclomine

DrugBank Accession Number

DB00804

Background

Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.^3,4,5,6 Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.⁷

Dicyclomine was granted FDA approval on 11 May 1950.⁶

Type

Small Molecule

Groups

Approved

Structure

Similar Structures

Weight: Average: 309.4867
Monoisotopic: 309.266779369
Chemical Formula: C₁₉H₃₅NO₂

Synonyms

2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate
Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester
Dicicloverina
Dicyclomine
Dicycloverin
Dicycloverine
Dicycloverinum

Pharmacology

Indication

Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.⁶

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines.⁶ It's duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection.⁶ Dicyclomine should not be administered intravenously.⁶

Mechanism of action

Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine.^3,4,5,6 Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum.⁴

Target	Actions	Organism
AMuscarinic acetylcholine receptor M1	antagonist	Humans
UMuscarinic acetylcholine receptor M3	antagonist	Humans
UMuscarinic acetylcholine receptor M2	antagonist	Humans

Absorption

The bioavailability of dicyclomine has not been determined,² though it is likely well absorbed as the primary route of elimination is in the urine.^1,6 Dicyclomine has a T_max of 1-1.5h.⁶

Volume of distribution

The volume of distribution for a 20mg oral dose is 3.65L/kg.⁶

Protein binding

Data regarding plasma protein binding of dicyclomine is not readily available.⁶

Metabolism

The metabolism of dicyclomine has not been well researched.¹

Route of elimination

Dicyclomine is 79.5% eliminated in the urine and 8.4% in the feces.^1,6

Half-life

The mean plasma elimination half life is approximately 1.8 hours.^1,6

Clearance

Data regarding the clearance of dicyclomine is not readily available.⁶

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Patients experiencing an overdose may present with headache, nausea, vomiting, blurred vision, dilated pupils, dizziness, dry mouth, difficulty swallowing, CNS stimulation, as well as hot, dry skin.⁶ Treat patients with gastric lavage, emetics, activated charcoal, sedatives for excitement, and a cholinergic agent if indicated.⁶

The oral LD₅₀ in mice is 625mg/kg.⁶

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	Dicyclomine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aceclofenac	Aceclofenac may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Acetaminophen	Acetaminophen may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Aclidinium	The risk or severity of adverse effects can be increased when Dicyclomine is combined with Aclidinium.
Acrivastine	Dicyclomine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Dicyclomine which could result in a higher serum level.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Avoid alcohol. Alcohol may increase drowsiness caused by dicyclomine.
Drink plenty of fluids. Dicyclomine may reduce sweating, increasing the risk of overheating in warm weather or during exercise.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Dicyclomine hydrochloride	CQ903KQA31	67-92-5	GUBNMFJOJGDCEL-UHFFFAOYSA-N

Product Images

International/Other Brands

Byclomine / Di-Spaz / Dibent / Dilomine / Dyspas (Savage) / Merbentyl (Sanofi)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bentyl	Syrup	10 mg/5mL	Oral	Axcan Scandipharm Inc.	2006-10-23	2006-10-23
Bentyl	Tablet	20.6 mg/1	Oral	Allergan, Inc.	1950-05-11	Not applicable
Bentyl	Tablet	20.6 mg/1	Oral	Physicians Total Care, Inc.	1950-05-11	2011-06-30
Bentyl	Injection, solution	20 mg/2mL	Intramuscular	A-S Medication Solutions	1952-08-13	Not applicable
Bentyl	Capsule	10 mg/1	Oral	Allergan, Inc.	1950-05-11	2018-08-31
Bentyl	Injection, solution	20 mg/2mL	Intramuscular	Allergan, Inc.	1952-08-13	Not applicable
Bentylol	Syrup	10 mg / 5 mL	Oral	Aptalis Pharma Canada Ulc	1993-12-31	2018-11-19
Bentylol Dospan 30mg	Tablet, extended release	30 mg / tab	Oral	Merrell Pharms Inc., Division Of Merrell Dow (Can)	1988-03-23	1996-09-09
Bentylol Inj 10mg/ml	Liquid	10 mg / mL	Intramuscular	Merrell Pharms Inc., Division Of Merrell Dow (Can)	1965-12-31	1996-09-09
Bentylol Tablet 10mg	Tablet	10 mg	Oral	Aptalis Pharma Canada Ulc	1995-12-31	2018-11-19

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Dicyclomine	Tablet	20 mg/1	Oral	Stat Rx USA	1996-10-01	Not applicable
Dicyclomine	Capsule	10 mg/1	Oral	NCS HealthCare of KY, LLC dba Vangard Labs	1997-02-28	2023-11-30
Dicyclomine	Tablet	20 mg/1	Oral	Pharmasource Meds, LLC	2023-03-14	Not applicable
Dicyclomine	Capsule	10 mg/1	Oral	Rebel Distributors	1997-02-28	Not applicable
Dicyclomine	Tablet	20 mg/1	Oral	Golden State Medical Supply, Inc.	1996-10-01	2017-01-02
Dicyclomine	Tablet	20 mg/1	Oral	Med Pharma Co., Ltd.	2011-01-10	2012-03-19
Dicyclomine	Tablet	20 mg/1	Oral	Liberty Pharmaceuticals, Inc.	1996-10-01	2015-03-05
Dicyclomine	Capsule	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Dicyclomine	Tablet	20 mg/1	Oral	Blenheim Pharmacal, Inc.	2011-04-01	Not applicable
Dicyclomine	Tablet	20 mg/1	Oral	Preferred Pharmaceuticals, Inc	1996-10-01	2019-08-23

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
RELESTAL PEDIATRIC SYRUP 10 mg/5 ml	Syrup	10 mg/5ml	Oral	FAR EAST DRUG COMPANY (PRIVATE) LIMITED	2003-04-25	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
ACOLIC SYRUP	Dicyclomine hydrochloride (5 mg/5ml) + Simethicone (50 mg/5ml)	Syrup	Oral	GOLDPLUS UNIVERSAL PTE LTD	1998-04-11	Not applicable
COLIMIX SYRUP	Dicyclomine hydrochloride (5 mg/5ml) + Simethicone (50 mg/5ml)	Syrup	Oral	APEX PHARMA MARKETING PTE. LTD.	1989-06-16	Not applicable
Diclophen	Dicyclomine hydrochloride (10 mg) + Phenobarbital (15 mg)	Capsule	Oral	Pro Doc Limitee	1970-12-31	2009-07-23
SPASMANOL PAEDIATRIC DROPS	Dicyclomine (10 MG/1ML) + Simethicone (40 MG/1ML)	Syrup	Oral	บริษัท ฟาร์มาแลนด์ (1982) จำกัด	2018-01-17	Not applicable
Spasmo Nil Tab	Dicyclomine hydrochloride (2.5 mg) + Aluminum hydroxide (75 mg) + Dimethicone (7.5 mg) + Magnesium trisilicate (75 mg)	Tablet	Oral	Duchesnay Inc.	1978-12-31	2003-07-18
ซิมโคมีน ไซรัป	Dicyclomine (5 MG/5ML) + Simethicone (50 MG/5ML)	Syrup	Oral	บริษัท ที.โอ.เคมีคอลส์ (1979) จำกัด	1995-10-25	2019-10-21
ซิมโคมีน ไซรัป	Dicyclomine (5 MG/5ML) + Simethicone (50 MG/5ML)	Syrup	Oral	บริษัท ที.โอ.ฟาร์ม่า จำกัด	2005-06-11	Not applicable
ยูเทอร์แกน	Dicyclomine (10 MG) + Mefenamic acid (250 MG)	Tablet		ห้างหุ้นส่วนจำกัด โรงงานเลิศสิงห์เภสัชกรรม	1997-01-09	Not applicable
สปัสทิโคน	Dicyclomine (5 MG/5ML) + Simethicone (50 MG/5ML)	Solution		บริษัท บางกอกแล็ป แอนด์ คอสเมติค จำกัด จำกัด	2000-10-15	2019-10-21
สปัสเด็ก	Dicyclomine (5 MG/5ML) + Simethicone (50 MG/5ML)	Syrup	Oral	บริษัท บางกอกแล็ป แอนด์ คอสเมติค จำกัด จำกัด	2000-02-01	2019-10-21

Chemical Identifiers

UNII: 4KV4X8IF6V
CAS number: 77-19-0
InChI Key: CURUTKGFNZGFSE-UHFFFAOYSA-N
InChI: InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
IUPAC Name: 2-(diethylamino)ethyl [1,1'-bi(cyclohexane)]-1-carboxylate
SMILES: CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1

References

Synthesis Reference

Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.

General References

Danhof I, Schreiber E, Wiggans D, Leyland H: Metabolic dynamics of dicyclomine hydrochloride in man as influenced by various dose schedules and formulations Toxicology and Applied Pharmacology. 1967 Dec 18;13(1):16-23. [Article]
Walker BJ, Lang JF, Okerholm RA: Quantitative analysis of dicyclomine in human plasma by capillary gas chromatography and nitrogen-selective detection. J Chromatogr. 1987 Apr 24;416(1):150-3. doi: 10.1016/0378-4347(87)80496-6. [Article]
Pavia J, Munoz M, Jimenez E, Martos F, Gonzalez-Correa JA, De la Cruz JP, Garcia V, Sanchez de la Cuesta F: Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes. Eur J Pharmacol. 1997 Feb 12;320(2-3):209-14. [Article]
MCGRATH WR, LEWIS RE, KUHN WL: THE DUAL MODE OF THE ANTISPASMODIC EFFECT OF DICYCLOMINE HYDROCHLORIDE. J Pharmacol Exp Ther. 1964 Dec;146:354-8. [Article]
Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA: Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther. 1987 Jul;242(1):257-62. [Article]
FDA Approved Drug Products: Dicyclomine Oral Capsules, Oral Tablets, and Intramuscular Injections [Link]
Canadian Agency for Drugs and Technologies in Health: Dicyclomine for Gastrointestinal Conditions: A Review of the Clinical Effectiveness, Safety, and Guidelines [Link]

External Links

Human Metabolome Database: HMDB0014942
KEGG Compound: C06951
PubChem Compound: 3042
PubChem Substance: 46505371
ChemSpider: 2934
BindingDB: 50010101
RxNav: 3361
ChEBI: 4514
ChEMBL: CHEMBL1123
ZINC: ZINC000001530613
Therapeutic Targets Database: DAP001118
PharmGKB: PA164744928
Guide to Pharmacology: GtP Drug Page
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Dicycloverine

FDA label

Download (230 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers

Axcan pharma us inc
Lannett co inc
Mutual pharmaceutical co inc
Mylan pharmaceuticals inc
Pioneer pharmaceuticals inc
Watson laboratories inc
West ward pharmaceutical corp
Bedford laboratories div ben venue laboratories inc
Alpharma us pharmaceuticals division
Mikart inc

Packagers

Advanced Pharmaceutical Services Inc.
Amerisource Health Services Corp.
Apotheca Inc.
A-S Medication Solutions LLC
Atlantic Biologicals Corporation
Axcan Pharma Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Bryant Ranch Prepack
Cardinal Health
Comprehensive Consultant Services Inc.
Dept Health Central Pharmacy
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Endo Pharmaceuticals Inc.
Gallipot
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Huffman Laboratories
International Ethical Labs Inc.
Lannett Co. Inc.
Liberty Pharmaceuticals
Major Pharmaceuticals
Merrell Pharmaceuticals Inc.
Mikart Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Patheon Inc.
Patient First Corp.
PCA LLC
PD-Rx Pharmaceuticals Inc.
Pharma Pac LLC
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Qualitest
Rebel Distributors Corp.
Redpharm Drug
Remedy Repack
Resource Optimization and Innovation LLC
Santec Chemicals Corp.
Southwood Pharmaceuticals
Stat Rx Usa
Taylor Pharmaceuticals
Tya Pharmaceuticals
UDL Laboratories
United Research Laboratories Inc.
Vangard Labs Inc.
Veratex Corp.
Watson Pharmaceuticals
West-Ward Pharmaceuticals

Dosage Forms

Form	Route	Strength
Capsule	Oral	10.000 mg
Syrup	Oral	10 mg/5mL
Tablet	Oral	20.6 mg/1
Syrup	Oral	10 mg / 5 mL
Tablet, extended release	Oral	30 mg / tab
Liquid	Intramuscular	10 mg / mL
Tablet	Oral	20 mg
Syrup	Oral
Syrup	Oral	5 mg/5ml
Capsule	Oral
Injection	Intramuscular	20 mg/2mL
Tablet	Oral	20 mg/1
Capsule	Oral	10 mg/1
Injection	Intramuscular	10 mg/1mL
Injection, solution	Intramuscular	10 mg/1mL
Injection, solution	Intramuscular	20 mg/2mL
Solution	Oral	10 mg/5mL
Syrup	Oral	10 mg/1mL
Tablet	Oral	10 mg/1
Solution	Intramuscular	10 mg / mL
Capsule	Oral	10 mg
Tablet	Oral
Tablet	Oral
Capsule	Oral	10 mg / cap
Tablet
Solution
Tablet, coated	Oral	10 mg
Tablet	Oral	10 mg
Suspension
Tablet, film coated
Tablet, film coated		10 mg

Prices

Unit description	Cost	Unit
Bentyl 10 mg/ml ampul	12.28USD	ml
Dicyclomine 10 mg/ml vial	8.58USD	ml
Dicyclomine Hydrochloride 10 mg/ml	3.41USD	ml
Dicyclomine hcl powder	1.0USD	g
Bentyl 10 mg capsule	0.79USD	capsule
Bentyl 20 mg tablet	0.75USD	tablet
Dicyclomine HCl 10 mg capsule	0.47USD	capsule
Dicyclomine HCl 20 mg tablet	0.4USD	tablet
Dicyclomine 20 mg tablet	0.31USD	tablet
Bentylol 20 mg Tablet	0.23USD	tablet
Bentyl 10 mg/5ml Syrup	0.15USD	ml
Bentylol 10 mg Tablet	0.12USD	tablet
Dicyclomine HCl 10 mg/5ml Solution	0.1USD	ml
Bentylol 2 mg/ml Syrup	0.06USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	165-166	Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.

Predicted Properties

Property	Value	Source
Water Solubility	0.00327 mg/mL	ALOGPS
logP	5.82	ALOGPS
logP	4.93	Chemaxon
logS	-5	ALOGPS
pKa (Strongest Basic)	8.96	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	29.54 Å²	Chemaxon
Rotatable Bond Count	8	Chemaxon
Refractivity	91.78 m³·mol^-1	Chemaxon
Polarizability	37.52 Å³	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	Yes	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.995
Blood Brain Barrier	+	0.9769
Caco-2 permeable	+	0.6616
P-glycoprotein substrate	Substrate	0.6141
P-glycoprotein inhibitor I	Non-inhibitor	0.6115
P-glycoprotein inhibitor II	Non-inhibitor	0.5806
Renal organic cation transporter	Inhibitor	0.5184
CYP450 2C9 substrate	Non-substrate	0.8373
CYP450 2D6 substrate	Non-substrate	0.8226
CYP450 3A4 substrate	Substrate	0.5092
CYP450 1A2 substrate	Inhibitor	0.9107
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Inhibitor	0.8932
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Inhibitor	0.796
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.6193
Ames test	Non AMES toxic	0.8524
Carcinogenicity	Non-carcinogens	0.52
Biodegradation	Not ready biodegradable	0.9876
Rat acute toxicity	3.1919 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.873
hERG inhibition (predictor II)	Inhibitor	0.6714

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-03di-0109000000-67a7b4058325a5b3b7b5

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Muscarinic acetylcholine receptor M1

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Antagonist

General Function: Phosphatidylinositol phospholipase c activity
Specific Function: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name: CHRM1
Uniprot ID: P11229
Uniprot Name: Muscarinic acetylcholine receptor M1
Molecular Weight: 51420.375 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Jin CH, Shin EJ, Park JB, Jang CG, Li Z, Kim MS, Koo KH, Yoon HJ, Park SJ, Choi WC, Yamada K, Nabeshima T, Kim HC: Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. J Neurosci Res. 2009 Dec;87(16):3658-70. doi: 10.1002/jnr.22159. [Article]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA: Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther. 1987 Jul;242(1):257-62. [Article]
Jiang ZW, Gong QZ, Di X, Zhu J, Lyeth BG: Dicyclomine, an M1 muscarinic antagonist, reduces infarct volume in a rat subdural hematoma model. Brain Res. 2000 Jan 3;852(1):37-44. doi: 10.1016/s0006-8993(99)02230-1. [Article]
Fornari RV, Moreira KM, Oliveira MG: Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory. Learn Mem. 2000 Sep-Oct;7(5):287-92. doi: 10.1101/lm.34900. [Article]

Details2. Muscarinic acetylcholine receptor M3

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Antagonist

General Function: Receptor activity
Specific Function: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name: CHRM3
Uniprot ID: P20309
Uniprot Name: Muscarinic acetylcholine receptor M3
Molecular Weight: 66127.445 Da

References

Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA: Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther. 1987 Jul;242(1):257-62. [Article]
Kilbinger H, von Bardeleben RS, Siefken H, Wolf D: Prejunctional muscarinic receptors regulating neurotransmitter release in airways. Life Sci. 1995;56(11-12):981-7. doi: 10.1016/0024-3205(95)00037-7. [Article]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	244	N/A	N/A	A28993

Details3. Muscarinic acetylcholine receptor M2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Antagonist

General Function: G-protein coupled acetylcholine receptor activity
Specific Function: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name: CHRM2
Uniprot ID: P08172
Uniprot Name: Muscarinic acetylcholine receptor M2
Molecular Weight: 51714.605 Da

References

Pavia J, Munoz M, Jimenez E, Martos F, Gonzalez-Correa JA, De la Cruz JP, Garcia V, Sanchez de la Cuesta F: Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes. Eur J Pharmacol. 1997 Feb 12;320(2-3):209-14. [Article]
Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA: Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther. 1987 Jul;242(1):257-62. [Article]

Drug created at June 13, 2005 13:24 / Updated at November 29, 2023 23:14

Dicyclomine

Identification

Structure for Dicyclomine (DB00804)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Targets

References

References

References